DOSING & ADMINISTRATION

The only biologic for AD
with Q4W dosing from the start1,2*

NEMLUVIO® OFFERS THE CONVENIENCE OF 1 INJECTION EVERY 4 WEEKS1

Image
A graphic showing that NEMLUVIO® is administered 13 times a year compared with the other biologics, which are administered 26 times a year
Image
A graphic showing that NEMLUVIO® is administered 13 times a year compared with the other biologics, which are administered 26 times a year

For pediatric patients weighing ≥66 lbs, dupilumab may be dosed Q4W.2

RECOMMENDED DOSING FOR ADULT AND ADOLESCENT PATIENTS (AGED ≥12) WITH AD1

Regardless of PATIENt weight

Initial DoseMaintenance Dose (Q4W)
2 injections1 injection

POSSIBILITY OF FLEXIBLE DOSING AFTER 16 WEEKS OF TREATMENT1

q4w
Consider for patients in whom additional clinical improvement is desired
q8w
Recommended dose for patients who are clear or almost clear

Defined as IGA 0, IGA 1, or EASI-75 is defined as a ≥75% improvement of lesion extent and severity.1

Each injection is 30 mg of NEMLUVIO1

NEMLUVIO is uniquely designed for patient satisfaction

Image

Room-temperature storage
for up to 90 days within the labeled expiration period1

Image

>75% lower volume
than dupilumab
(0.49 mL vs 2 mL)1,2‡

Image

Convenience
of a prefilled
self-injectable pen1

A photograph of a NEMLUVIO® single-dose, pre-filled, dual-chamber pen.

Administer NEMLUVIO seamlessly and safely

A photograph of a NEMLUVIO® single-dose, pre-filled, dual-chamber pen.

Unlock the auto-injector pen by turning the knob to the right—only once

 

Shake for 30 SECONDS in an upright position to reconstitute

 

Wait for 5 MINUTES until the bubbles have faded and the powder has dissolved completely

 

Twist the gray cap gently counterclockwise while holding upright until the orange needle guard pops up

 

Inject for 15 SECONDS with the pen flat on the skin

The NEMLUVIO Instructions for Use should be read carefully before using NEMLUVIO

Watch the NEMLUVIO Demo Kit Video to see how to successfully administer NEMLUVIO to your patients

 

Visit the NEMLUVIO Patient Site to watch an injection training video for self-administering patients

What patients should know before getting started

  • Keep the NEMLUVIO pen and all medicines out of the reach of children3
  • It is best to store the NEMLUVIO pen in the refrigerator between 36 °F and 46 °F (2 °C to 8 °C)3
    • However, the NEMLUVIO pen can be stored at room temperature up to 77 °F (25 °C) for a single period up to 90 days3
    • Take the NEMLUVIO pen out of the refrigerator and let it come to room temperature for 30 to 45 minutes before continuing3
  • After the medicine has dissolved, it must be used within 4 hours. If you have not used it within 4 hours, dispose of it3
  • Patients should mark their calendar ahead of time to remember when to take NEMLUVIO3
  • The NEMLUVIO pen should not be used if it has been dropped on a hard surface or is damaged, cracked, or broken3
  • The used NEMLUVIO pen should be disposed of right away after use in a sharps disposal container3
  • Patients should be encouraged to complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to NEMLUVIO treatment initiation1

Where to inject

  • Select the injection site using the following chart3
    • Inject the pen in the abdomen (2 inches away from the navel), upper thigh, or the outer upper arm3
    • Use a different injection site at least 1 inch away from the first injection site3
Image
A graphic showing the outline of a person with areas highlighted on the upper arms, abdomen, and thighs showing where NEMLUVIO® may be self-injected or administered by a caregiver.
Image
A graphic showing the outline of a person with areas highlighted on the upper arms, abdomen, and thighs showing where NEMLUVIO® may be self-injected or administered by a caregiver.
Image
GPS (Galderma Patient Services) for NEMLUVIO™ logo.

GPS (Galderma Patient Services) for NEMLUVIO™

Helps patients start and stay on treatment by providing access to assistance programs and adherence support

Image

Patient and Practice Resources

Tools to help patients start and stay on treatment

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.